GlassScriptPhysician profile
Jennifer C Bailey
NPI 1447431465
$2,057.18
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $192 · 2021: $411 · 2022: $488 · 2023: $288 · 2024: $238 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.05 | 2020-2023 | Liletta, Lo Loestrin Fe |
| Organon LLC | $208.19 | 2021-2025 | Nexplanon, Jada System |
| Astellas Pharma US INC | $166.23 | 2021-2025 | Veozah |
| Hologic Sales and Service, LLC | $160.82 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Amgen INC. | $146.24 | 2019-2024 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $105.17 | 2022-2025 | |
| Meditrina | $91.36 | 2022 | |
| Agile Therapeutics, INC. | $67.48 | 2021-2023 | Twirla |
| Daiichi Sankyo INC. | $57.29 | 2019-2024 | Injectafer |
| Coopersurgical, INC. | $53.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.07 | 2021-2023 | |
| Lupin INC. | $49.88 | 2019-2021 | |
| Boston Scientific Corporation | $49.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.49 | 2022-2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $36.06 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.26 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $34.75 | 2024-2025 | |
| Millicent US INC | $17.84 | 2024 | Femring, Intrarosa |
| Baxter Healthcare | $17.31 | 2019 | |
| Gilead Sciences, INC. | $16.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.